The occurrence of anaphylactoid and other hyperergic reactions have been reported occassionally following the use of mesna. This risk is approx. 3.5 times higher in patients with autoimmune disease than in patients with tumour disease (without autoimmune disease).
Skin and mucous membrane reactions (urticaria, itching, exanthema, enanthema), increase in transaminases and general symptoms such as fever, exhaustion, nausea and vomiting occurred. Circulatory reactions such as fall in blood pressure and tachycardia have been observed rarely. Local oedema occurred in isolated cases; in rare cases venous irritation at the injection site.
In a tolerability study with high oral or intravenous doses of mesna, nausea, vomiting, diarrhoea, headache and limb pain, fall in blood pressure and tachycardia, skin reactions, exhaustion and weakness occurred, when a single dose of 60 mg/kg body weight was administered.
During treatment, the undesirable effects mentioned above cannot always be distinguished from those of the oxazaphosphorines (ifosfamide, cyclophosphamide, trofosfamide) or other concomitant medication.